ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $35.45 billion. The enterprise value is $35.85 billion.
Market Cap | 35.45B |
Enterprise Value | 35.85B |
Important Dates
The last earnings date was Thursday, October 24, 2024, after market close.
Earnings Date | Oct 24, 2024 |
Ex-Dividend Date | Nov 7, 2024 |
Share Statistics
ResMed has 146.75 million shares outstanding. The number of shares has increased by 0.02% in one year.
Current Share Class | 146.75M |
Shares Outstanding | 146.75M |
Shares Change (YoY) | +0.02% |
Shares Change (QoQ) | +0.04% |
Owned by Insiders (%) | 0.53% |
Owned by Institutions (%) | 73.72% |
Float | 145.81M |
Valuation Ratios
The trailing PE ratio is 32.04 and the forward PE ratio is 25.22. ResMed's PEG ratio is 1.59.
PE Ratio | 32.04 |
Forward PE | 25.22 |
PS Ratio | 7.38 |
Forward PS | n/a |
PB Ratio | 6.82 |
P/TBV Ratio | 19.37 |
P/FCF Ratio | 26.19 |
P/OCF Ratio | 24.61 |
PEG Ratio | 1.59 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.97, with an EV/FCF ratio of 26.50.
EV / Earnings | 32.22 |
EV / Sales | 7.46 |
EV / EBITDA | 21.97 |
EV / EBIT | 24.19 |
EV / FCF | 26.50 |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 0.16.
Current Ratio | 2.92 |
Quick Ratio | 1.44 |
Debt / Equity | 0.16 |
Debt / EBITDA | 0.51 |
Debt / FCF | 0.63 |
Interest Coverage | 40.98 |
Financial Efficiency
Return on equity (ROE) is 23.56% and return on invested capital (ROIC) is 15.72%.
Return on Equity (ROE) | 23.56% |
Return on Assets (ROA) | 13.27% |
Return on Capital (ROIC) | 15.72% |
Revenue Per Employee | $481,712 |
Profits Per Employee | $111,511 |
Employee Count | 9,980 |
Asset Turnover | 0.69 |
Inventory Turnover | 1.82 |
Taxes
In the past 12 months, ResMed has paid $263.22 million in taxes.
Income Tax | 263.22M |
Effective Tax Rate | 19.13% |
Stock Price Statistics
The stock price has increased by +62.18% in the last 52 weeks. The beta is 0.69, so ResMed's price volatility has been lower than the market average.
Beta (5Y) | 0.69 |
52-Week Price Change | +62.18% |
50-Day Moving Average | 242.11 |
200-Day Moving Average | 213.51 |
Relative Strength Index (RSI) | 50.05 |
Average Volume (20 Days) | 1,185,577 |
Short Selling Information
The latest short interest is 7.89 million, so 5.38% of the outstanding shares have been sold short.
Short Interest | 7.89M |
Short Previous Month | 8.57M |
Short % of Shares Out | 5.38% |
Short % of Float | 5.41% |
Short Ratio (days to cover) | 7.18 |
Income Statement
In the last 12 months, ResMed had revenue of $4.81 billion and earned $1.11 billion in profits. Earnings per share was $7.54.
Revenue | 4.81B |
Gross Profit | 2.80B |
Operating Income | 1.48B |
Pretax Income | 1.26B |
Net Income | 1.11B |
EBITDA | 1.63B |
EBIT | 1.48B |
Earnings Per Share (EPS) | $7.54 |
Balance Sheet
The company has $442.58 million in cash and $850.24 million in debt, giving a net cash position of -$407.67 million or -$2.78 per share.
Cash & Cash Equivalents | 442.58M |
Total Debt | 850.24M |
Net Cash | -407.67M |
Net Cash Per Share | -$2.78 |
Equity (Book Value) | 5.20B |
Book Value Per Share | 35.39 |
Working Capital | 1.74B |
Cash Flow
In the last 12 months, operating cash flow was $1.44 billion and capital expenditures -$87.27 million, giving a free cash flow of $1.35 billion.
Operating Cash Flow | 1.44B |
Capital Expenditures | -87.27M |
Free Cash Flow | 1.35B |
FCF Per Share | $9.22 |
Margins
Gross margin is 58.33%, with operating and profit margins of 30.84% and 23.15%.
Gross Margin | 58.33% |
Operating Margin | 30.84% |
Pretax Margin | 28.62% |
Profit Margin | 23.15% |
EBITDA Margin | 33.95% |
EBIT Margin | 30.84% |
FCF Margin | 27.78% |
Dividends & Yields
This stock pays an annual dividend of $2.12, which amounts to a dividend yield of 0.88%.
Dividend Per Share | $2.12 |
Dividend Yield | 0.88% |
Dividend Growth (YoY) | 9.78% |
Years of Dividend Growth | 12 |
Payout Ratio | 28.12% |
Buyback Yield | -0.02% |
Shareholder Yield | 0.85% |
Earnings Yield | 3.14% |
FCF Yield | 3.82% |
Analyst Forecast
The average price target for ResMed is $227.63, which is -5.76% lower than the current price. The consensus rating is "Buy".
Price Target | $227.63 |
Price Target Difference | -5.76% |
Analyst Consensus | Buy |
Analyst Count | 11 |
Revenue Growth Forecast (5Y) | 7.84% |
EPS Growth Forecast (5Y) | 13.72% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
Last Split Date | Aug 31, 2010 |
Split Type | Forward |
Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 10.95 and a Piotroski F-Score of 6.
Altman Z-Score | 10.95 |
Piotroski F-Score | 6 |